Shree Kurup (Winston Salem, NC, USA), Ahmad Mansour (Lebanon), J. Arevalo (Venezuela)


Inflammatory choroidal neovascularization (CNV) is a potentially blinding complication in uveitis. In patients already on immunosuppressive, intraocular medications are reasonable options without increasing systemic toxicity.


Retrospective multicenter consecutive case series of inflammatory ocular neovascularization in 81 patients over 3 years.


Intravitreal injection of bevacizumab.

Main Outcome Measures:

Improvement of best-corrected visual acuity (BCVA), expressed as logarithm of minimum angle of resolution (logMar), and decrease in central foveal thickness (CFT) as measured by optical coherence tomography.

Effectiveness / Safety:

At 3 years, intravitreal bevacizumab sustained significant visual improvement of about 3 lines and significant foveal flattening close to 100 microns, in a wide variety of inflammatory ocular diseases, without major complications after a median of 3 injections

Take home message:

Consider Avastin in selected patients with CNV in uveitis, as second line therapy. Be aware of risk to benefit ratio.